Method that rapidly predicts breast cancer survival rates clinically validated

Digistain, a company with its roots at Imperial, has proven the worth of its breast cancer assessment method in a significant clinical trial.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart